Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for INmune Bio, Inc. (INMB : NSDQ)

• Company Description    INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company's product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient's NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio Inc. is based in La Jolla, United States. Number of Employees: 22

• Price / Volume Information    Yesterday's Closing Price: $1.56 Daily Weekly Monthly 20 Day Moving Average: 437,095 shares Shares Outstanding: 26.58 (millions) Market Capitalization: $41.47 (millions) Beta: 0.70 52 Week High: $11.64 52 Week Low: $1.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.02% -16.88% 12 Week -21.21% -22.48% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 225 NE Mizner Blvd. Suite 640 - Boca Raton,FL 33432 USA ph: 561-710-0512 fax: - dcarlson@inmunebio.com http://www.inmunebio.com

• General Corporate Information    Officers Raymond J. Tesi - Chief Executive Officer and President David J. Moss - Chief Financial Officer; Treasurer; Secretary Timothy Schroeder - Director J. Kelly Ganjei - Director Scott Juda - Director Peer Information INmune Bio, Inc. (CORR.) INmune Bio, Inc. (RSPI) INmune Bio, Inc. (CGXP) INmune Bio, Inc. (BGEN) INmune Bio, Inc. (GTBP) INmune Bio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45782T105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 26.58 Most Recent Split Date: (:1) Beta: 0.70 Market Capitalization: $41.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.63 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 60.00% vs. Previous Quarter: 29.41% Sales Growth vs. Year Ago Period: 257.14% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -115.06 06/30/25 - -120.62 ROA 12/31/25 - - 09/30/25 - -89.95 06/30/25 - -92.94 Current Ratio 12/31/25 - - 09/30/25 - 4.17 06/30/25 - 4.20 Quick Ratio 12/31/25 - - 09/30/25 - 4.17 06/30/25 - 4.20 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -99,774.00 06/30/25 - -111,016.00 Book Value 12/31/25 - - 09/30/25 - 0.95 06/30/25 - 1.22 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©